Back to Authors

François, Sylvie

A5082128886 | I4210112910

Mayo Clinic

Centre Hospitalier Universitaire d'Angers

Citations 1

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma

Blood | January 10, 2017 | Volume: 129 | Issue: 10 | Pages: 1380-1388

10.1182/blood-2016-09-738385 | PMID 28073785

Key Points HSCT after PD-1 blockade is feasible, although may be associated with increased early immune toxicity. PD-1 blockade may cause persistent depletion of PD1+ T cells and alterations in T-cell differentiation impacting subsequent treatment.